Therapeutic value of endoscopic ultrasound-guided pancreatic duct drainage (with video)
10.3760/cma.j.cn321463-20231225-00648
- VernacularTitle:超声内镜引导下胰管引流的临床疗效分析（含视频）
- Author:
Shanshan SHEN
1
;
Shuang NIE
;
Wen LI
;
Ruhua ZHENG
;
Wei CAI
;
Zhengyan QIN
;
Bin ZHANG
;
Ying LYU
;
Xiaoping ZOU
;
Lei WANG
Author Information
1. 南京大学医学院附属鼓楼医院消化内科，南京 210008
- Keywords:
Cholangiopancreatography, endoscopic retrograde;
Endoscopic ultrasound;
Pancreatic duct drainage;
Pancreatic duct stent
- From:
Chinese Journal of Digestive Endoscopy
2024;41(11):889-894
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effectiveness and safety of endoscopic ultrasound-guided pancreatic duct drainage (EUS-PD).Methods:A retrospective analysis was conducted on data of 16 patients who underwent EUS-PD because of endoscopic retrograde pancreatography (ERP) failure, poor effectiveness or anatomical changes and couldn't undergo the routine ERP in Nanjing Drum Tower Hospital from June 2018 to July 2022. The technical success of EUS-PD, clinical efficacy and post-procedure adverse events were analyzed.Results:In the 16 patients, there were 14 males and 2 females, with age of 50.69±12.95 years. A total of 19 times of EUS-PD operations were included, 3 of them were rendezvous-assisted endoscopic retrograde pancreatography (RV-ERP), 15 transgastric or transenteric EUS-guided stent placement and 1 was EUS-guided nasopancreatic duct placement. Technical success was achieved in 84.21% (16/19) patients, and among whom 93.75% (15/16) achieved clinical success. The overall incidence of postoperative adverse events was 52.63% (10/19) including 47.37% (9/19) abdominal pain, 15.79% (3/19) fever and 15.79% (3/19) postoperative pancreatitis. All adverse effects were relieved after general conservative treatment and no primary disease or surgery-related death occurred. The mean follow-up was 17.6 (8.2,22.3) months and 93.75% (15/16) of the patients were followed up. By the time of follow-up, 76.92% (10/13) of the patients who had successfully received EUS-PD had no recurrence of abdominal pain or distension.Conclusion:EUS-PD is a safe and effective alternative therapy for those with pancreatic diseases with ERP failure, poor efficacy or anatomical changes.
